Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience-Reference-Cited by-同舟云学术

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience

Published:2019-01 Issue: Volume:Volume 13 Page:13-21
ISSN:1177-5491
Container-title:Biologics: Targets and Therapy
language:en
Short-container-title:BTT

Author:

Alvisi Patrizia,Arrigo Serena,Cucchiara Salvatore,Lionetti Paolo,Miele Erasmo,Romano Claudio,Ravelli Alberto,Knafelz Daniela,Martelossi Stefano,Guariso Graziella,Accomando Salvatore,Zuin Giovanna,De Giacomo Costantino,Balzani Lucio,Gennari Monia,Aloi Marina

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Gastroenterology,Oncology,Rheumatology,Immunology and Allergy

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of adalimumab in pediatric patients with Crohn’s disease: A systematic review and meta-analysis;European Journal of Clinical Pharmacology;2023-12-29

2. Adalimumab in Pediatric Inflammatory Bowel Disease;Frontiers in Pediatrics;2022-04-13

3. Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease;Scandinavian Journal of Gastroenterology;2021-09-21

4. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis;Journal of Clinical Medicine;2021-05-14

5. Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease;Frontiers in Pediatrics;2021-05-04